Executives from Travere Therapeutics (NASDAQ:TVTX) said the company is focused on advancing treatments in three rare diseases ...

Travere Therapeutics’ updated fair value estimate of $42.36, up from $41.64, reflects fresh Street research that is reworking revenue growth expectations and the risk profile around the Filspari ...

Travere (TVTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report fourth quarter and full year 2025 financial results on Thursday, February 19, 2026, after the close of the U.S. financial ...

Travere Therapeutics is focused on rare kidney diseases, with FILSPARI driving significant revenue growth in IgA Nephropathy (IgAN). Competition in IgAN from larger players like Novartis and Vertex is ...

Wall Street expects a year-over-year increase in earnings on higher revenues when Kiniksa Pharmaceuticals International, plc (KNSA) reports results for the quarter ended December 2025. While this ...

Travere Therapeutics, Inc. today announced that company management will present at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Wednesday, February 11, 2026, at 4:00 p.m. ET. A live webcast ...

The purchase of Travere Therapeutics shares by Palisades Investment Partners is noteworthy because it represented a new position for the investment firm. The transaction came in the fourth quarter of ...

On the same dates, Dube exercised options to acquire 60,000 shares of Travere Therapeutics common stock at a price of $15.46, for a total value of $927600. In other recent news, Travere Therapeutics ...

BOSTON, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Travere Therapeutics, Inc. (Nasdaq: TVTX) for potential securities law violations. Investors who have lost money in their ...

Travere Therapeutics Inc. (NASDAQ:TVTX) is one of the best mid-cap growth stocks to buy right now. On January 14, Bank of America lowered its price target on Travere Therapeutics to $43 from $47, ...